NCT06449859

A Clinical Trial of TQC2938 Injection in Healthy Adult Subjects

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of TQC2938 Injection in Healthy Adult Subjects After Single and Multiple Administration

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 84 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The study is designed in two phases: single-dose administration and multiple-dose administration. A randomized, double-blind, placebo-controlled trial design was used to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity of TQC2938 injection in healthy adults.

Conditions

• Asthma

Interventions

Type	Name	Description
DRUG	TQC2938 Injection	TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.
DRUG	TQC2938 Placebo	TQC2938 Placebo is a placebo comparator

Timeline

• Start date: 2023-06-13
• Primary completion: 2024-11-01
• Completion: 2024-11-01
• First posted: 2024-06-10
• Last updated: 2024-06-10

Locations

1 site across 1 country: China